Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial.

ABSTRACT:

SUBMITTER: Marsden J 

PROVIDER: S-EPMC10692661 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature